NCT00005857View on ClinicalTrials.gov

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2000

Primary Completion Date

October 31, 2002

Study Completion Date

October 31, 2002

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

trastuzumab

DRUG

docetaxel

Trial Locations (4)

95817

University of California Davis Cancer Center, Sacramento

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Duarte

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

02135

St. Elizabeth's Medical Center of Boston, Brighton

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00005857 - Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | Biotech Hunter | Biotech Hunter